Source comparison
Thymosin Alpha-1 Chronic Fatigue: Treatment Comparison
Thymosin Alpha-1 TLR9 activation, T-cell maturation, NK cell enhancement Moderate (2 RCTs, multiple open-label studies) 6–12 weeks for symptom improvement Injection-site reactions (15–40%), mild flu-like symptoms in first week Most promising for CFS patients w
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- TLR9 activation, T-cell maturation, NK cell enhancement
- Moderate (2 RCTs, multiple open-label studies)
- 6–12 weeks for symptom improvement
- Injection-site reactions (15–40%), mild flu-like symptoms in first week
- Most promising for CFS patients with documented immune dysfunction and elevated inflammatory markers; requires baseline immune profiling for optimal patient selection
- Low-Dose Naltrexone
- Opioid receptor modulation, endorphin upregulation
- Moderate (multiple small trials, large observational data)
- 4–8 weeks
- Vivid dreams, initial insomnia (20–30%)
- Effective for pain and sleep in CFS but less consistent impact on post-exertional malaise; works via different pathway than immune modulation
- Rituximab (B-cell Depletion)
- B-cell targeting, autoantibody reduction
- Low (initial promise not replicated in phase III)
- 12–24 weeks in responders
- Infusion reactions, increased infection risk
- Early trials showed benefit, but larger RCTs failed to replicate; mechanism may be relevant only in autoimmune-driven CFS subset
- Coenzyme Q10 + NADH
- Mitochondrial electron transport support
- Weak (small trials, mixed results)
- 8–12 weeks
- Minimal; GI upset in <5%
- Addresses energy metabolism directly but doesn't modify immune dysfunction; may work synergistically with immune therapies rather than as monotherapy